Yoav Golan is an Infectious Disease physician affiliated with Tufts University. OpenAlex indexes 95 publications with 5,810 citations (h-index 34); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
750 Washington St
Nemc Box #836
Boston, MA 021111526
Telephone
617-636-5000Registry record last updated 8 Jul 2007.
Clinical trials
- A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
Sponsor: Tarsus Pharmaceuticals, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Paratek Pharmaceuticals, Inc.Program year202572 payments$95,833openpaymentsdata.cms.gov ↗
- Aimmune Therapeutics, Inc.Program year202515 payments$16,031openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor65%Descovy50%Triumeq50%Part D<11 patientsTetracycline-class Drug35%Doxycycline Hyclate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2013–2014 per NIH RePORTER. The latest:
- Role of Bile Acids in Human Susceptibiity to Clostridium difficile Infection
Tufts University Boston
FY2014$195,710R21AI107640 - Role of Bile Acids in Human Susceptibiity to Clostridium difficile Infection
Tufts University Boston
FY2013$255,581R21AI107640
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Dual Antiviral Therapy for Persistent Coronavirus Disease 2019 and Associated Organizing Pneumonia in an Immunocompromised Host
Clinical Infectious Diseases
2022 - Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial
Clinical Infectious Diseases
2022
Similar KOLs
Other experts from the same institution or the same specialty.
David Snydman, MD
Tufts University
Gitanjali M Singh
Tufts University
Jay Duker, MD
Tufts University
Richard Karas, MD
Tufts University
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”